Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p58
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 58/66)
Character Range: 187003–192055

Authority Required procedures - Streamlined Authority Code 16104
                                                      Initial treatment
                                                      Must be treated by a neurologist; or
                                                      Must be treated by a general practitioner in consultation with a neurologist; AND
                                                      Patient must not be undergoing concurrent treatment with the following PBS benefits: (i) botulinum toxin type A listed for this PBS indication, (ii) another drug in the same pharmacological class as this drug listed for this PBS indication; AND
                                                      Patient must have experienced at least 8 migraine headache days per month, over a period of at least 6 months, prior to commencement of treatment with this medicine for this condition; AND
                                                      Patient must have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications prior to commencement of treatment with this drug for this condition; AND
                                                      Patient must be appropriately managed by their practitioner for medication overuse headache, prior to initiation of treatment with this drug;
                                                      Patient must be at least 18 years of age.
                                                      Prophylactic migraine medications are propranolol, amitriptyline, pizotifen, candesartan, verapamil, nortriptyline, sodium valproate or topiramate.
                                                      Patient must have the number of migraine headache days per month documented in their medical records.
C16111  P16111  CN16111  Perhexiline                  Angina                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 16111
                                                      The condition must not be responding to other therapy; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16114  P16114  CN16114  Fluconazole                  Fungal infection                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 16114
                                                      The condition must be serious or life-threatening; AND
                                                      Patient must be unable to take a solid dose form of fluconazole; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16115  P16115  CN16115  Voriconazole                 Prophylaxis of invasive fungal infections including both yeasts and moulds                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures
                                                      Patient must be considered at high risk of developing an invasive fungal infection due to anticipated neutropenia (an absolute neutrophil count less than 500 cells per cubic millimetre) for at least 10 days whilst receiving chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome; or
                                                      Patient must be considered at high risk of developing an invasive fungal infection due to having acute graft versus host disease (GVHD) grade II, III or IV, or, extensive